Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Vertex Pharmaceuticals Incorporated keeps $33 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 2
in 29 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Vertex Pharmaceuticals beat revenue expectations but missed on adjusted EPS in the second fiscal quarter of 2026, reported Aug. 3, as revenue rose 12.5% to about $3.3 billion from about $3.0 billion a year ago, above the about $3.2 billion consensus by +3.2%, while adjusted EPS of $4.73, up 4.6% from $4.52 a year ago, came in below the $4.74 estimate by -0.2%. Gross margin held near 85% and operating margin near 37%, and net income rose 6.5% to about $1.1 billion from $1.03 billion a year ago. Vertex generated operating cash flow of $1.13 billion and repurchased about $470 million of stock. Consensus for the next period calls for EPS of $4.80 on revenue of $3.40 billion.
Next report — what to expect
Vertex Pharmaceuticals Incorporated reports earnings on November 2, 2026. Wall Street is looking for consensus EPS of $4.76 on consensus revenue of $3.41 billion. For trailing context, revenue grew +12.5% year over year last quarter. Vertex has beaten EPS in 4 of 8 most recent quarters, so attention may center on results versus these benchmarks.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated develops and markets prescription medicines in biotechnology, centered on cystic fibrosis treatments and a broader genetic-disease pipeline. The NASDAQ-listed company generated $12.1 billion of revenue in FY2025. Its marketed portfolio includes TRIKAFTA for cystic fibrosis patients with at least one F508del mutation, along with KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI.
Today's Snapshot
VRTX ended the day slightly lower at 504.60, in line with a flat sector.
Trading Volume
Below 10d avg (999.5K)
935.6K
vs S&P 500 Today
Underperforming Market
-1.20%
Updated: October 2, 2026 at 20:22 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$477.66 - $519.82Sell
- RSI (14)39.03Neutral
- Stochastic %K (14, 3, 3)37.10Neutral
- MACD Level (12, 26)-2.44Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.